sorafenib has been researched along with 1,2,5,8-tetrahydroxy anthraquinone in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (1,2,5,8-tetrahydroxy anthraquinone) | Trials (1,2,5,8-tetrahydroxy anthraquinone) | Recent Studies (post-2010) (1,2,5,8-tetrahydroxy anthraquinone) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 48 | 0 | 34 |
| Protein | Taxonomy | sorafenib (IC50) | 1,2,5,8-tetrahydroxy anthraquinone (IC50) |
|---|---|---|---|
| Urokinase-type plasminogen activator | Homo sapiens (human) | 4.4 | |
| Tissue-type plasminogen activator | Homo sapiens (human) | 4.4 | |
| Plasminogen activator inhibitor 1 | Homo sapiens (human) | 4.4 | |
| Urokinase-type plasminogen activator | Mus musculus (house mouse) | 4.4 | |
| Casein kinase II subunit alpha | Rattus norvegicus (Norway rat) | 0.11 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 3.0815 | |
| Casein kinase II subunit beta | Rattus norvegicus (Norway rat) | 0.11 | |
| Casein kinase II subunit alpha | Homo sapiens (human) | 0.11 | |
| Integrase | Human immunodeficiency virus 1 | 2.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Ashmawy, MB; El-Gohary, NS; Shehata, IA; Warda, ET | 1 |
1 other study(ies) available for sorafenib and 1,2,5,8-tetrahydroxy anthraquinone
| Article | Year |
|---|---|
New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.
Topics: Apoptosis; Binding Sites; Caspase 3; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Humans; Isoxazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2020 |